About the Study : Results of this study suggest that substitution effects are possible between obesity-labeled and diabetes-labeled GLP-1 RAs, varying by state coverage policies, that could impact coverage decisions.
Corresponding Author: Michael C. Wang, MD, Department of Medicine, University of Pennsylvania Perelman School of Medicine, 3600 Civic Center Blvd, 7F, Philadelphia, PA 19104 ( michael.wang2@pennmedicine.upenn.edu ).
10.1001/jamahealthforum.2026.3353
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.3353?guestAccessKey=aca3a8ab-c716-4ebe-acb2-54baec3ac94e
Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
JAMA Health Forum